Fig. 1: Multimodal debulking results in sBCMA clearance and subsequent response to BCMA× CD3 bispecific antibodies. | Leukemia

Fig. 1: Multimodal debulking results in sBCMA clearance and subsequent response to BCMA× CD3 bispecific antibodies.

From: Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Fig. 1

A Design of study including sBCMA-levels (ng/mL) in peripheral blood (PB), bone marrow (BM) and ultrafiltrate (UF) before and after plasmapheresis. B IgA levels in PB (mg/dL) and sBCMA levels (ng/mL) in BM and PB over the course of treatment, graphical view (upper panel), tabular view (lower panel). Abbreviations: Tec, teclistamab, PP plasmapheresis, D-P(A)CE daratumumab, cisplatin, cyclophosphamide, etoposide. Figure 1A created in BioRender under license https://BioRender.com/9gtlmss.

Back to article page